Carl read the papersWhat it actually is
Semaglutide mimics GLP-1, a gut hormone that signals fullness and helps regulate blood sugar. It slows stomach emptying and reduces appetite, which drives weight loss.
Unlike most peptides here, semaglutide is an approved medicine (Ozempic for diabetes, Wegovy for weight management) with large human trials behind it.
How it’s thought to work
- Appetite signalling — activates GLP-1 receptors in the brain to increase satiety.
- Slowed gastric emptying — food leaves the stomach slower, so you feel full longer.
- Glucose control — boosts insulin and lowers glucagon in response to meals.
- Long half-life — engineered to last ~1 week, allowing weekly dosing.
What the research says
Backed by large randomized human trials (STEP, SUSTAIN) showing significant weight loss and glucose improvement. This is one of the best-evidenced compounds in the guide.
- Clinically significant weight loss (~15% in trials).
- Type-2 diabetes glucose control.
- Proven heart benefit: in SELECT, in people with heart disease and overweight, it cut the combined risk of heart attack, stroke or heart death by 20%, and Wegovy is now approved for that. Ozempic also has a kidney label and Wegovy a fatty-liver (MASH) label.
Watch: Semaglutide explained
Video by Harvard Medical School Continuing Education on YouTube. Not affiliated with Peptide Carl and not an endorsement — included because a second explanation of the same mechanism is often what makes it click.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Community dose | 0.05–0.25 mg microdose to start; ladder 0.25→0.5→1.0→1.7→2.4 mg |
| Frequency | Once weekly (some split 2× / week) |
| Route | Subcutaneous |
| Titration | Hold each step 8–12 weeks — “low and slow” |
| Community tip | Lower dose = far less nausea; stay where it still works |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Weight loss | microdose → 2.4 mg/wk, low & slow titration |
| Type-2 diabetes | Ozempic, weekly titrated |
| Ease side-effects (The Reset) | + BPC-157 for GI comfort |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
SubQ once weekly (abdomen/thigh/upper arm, rotate). Titrate slowly — 0.05–0.25 mg to start, holding each step 8–12 weeks. It’s a pen/prescription product; store per label (fridge before first use).
Stacks it appears in
- The Reset — Semaglutide + BPC-157 — a community pairing meant to ease GLP-1 stomach side-effects. No trial has tested it.
Sources
- STEP 1 semaglutide 2.4 mg, NEJM 2021 (PMID 33567185)
- SUSTAIN-6, NEJM 2016 (PMID 27633186)
- SELECT heart outcomes, NEJM 2023 (PMID 37952131)
- FLOW kidney outcomes, NEJM 2024 (PMID 38785209)
- ESSENCE MASH trial, NEJM 2025 (PMID 40305708)
- SURMOUNT-5 tirzepatide vs semaglutide, NEJM 2025 (PMID 40353578)
- FDA label: Wegovy injection and tablets (DailyMed, Jun 2026)
- FDA label: Ozempic injection (DailyMed, Jun 2026)
- Drugs@FDA: NDA 215256 (Wegovy), approved 4 Jun 2021
